AWH vs. ICCC, ABIO, VNRX, OCX, CDIO, TRIB, BMRA, TKNO, ACHV, and LFWD
Should you be buying Aspira Women's Health stock or one of its competitors? The main competitors of Aspira Women's Health include ImmuCell (ICCC), ARCA biopharma (ABIO), VolitionRx (VNRX), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and ReWalk Robotics (LFWD). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
ImmuCell has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
Aspira Women's Health has a consensus price target of $4.45, suggesting a potential upside of 28.99%. Given ImmuCell's higher possible upside, analysts clearly believe Aspira Women's Health is more favorable than ImmuCell.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 6.3% of ImmuCell shares are held by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 30.95% of users gave Aspira Women's Health an outperform vote.
In the previous week, ImmuCell had 1 more articles in the media than Aspira Women's Health. MarketBeat recorded 2 mentions for ImmuCell and 1 mentions for Aspira Women's Health. Aspira Women's Health's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.
ImmuCell has a net margin of -33.05% compared to ImmuCell's net margin of -176.74%. Aspira Women's Health's return on equity of -21.79% beat ImmuCell's return on equity.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 16 factors compared between the two stocks.
Get Aspira Women's Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AWH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AWH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspira Women's Health Competitors List
Related Companies and Tools
